The immune response against citrullinated antigens is a hallmark of ACPA+ patients with RA, although it remains uncertain whether RA can be truly divided into two clinical subtypes with distinct mechanisms of immune-dysregulation based solely on serum ACPA status. This evidence concerns the gene PRTN3 and rheumatoid arthritis.